Exosome is a kind of single-membrane microvesicles with phospholipid bilayer structure secreted by cells, with a diameter of about 30-200 nm and a density of 1.1-1.2g/ml, naturally present in each cell. In a complex biological fluid, including blood, urine, saliva, breast milk and cerebrospinal fluid, almost all types of cells (tumor cells, immune cells, stem cells) including nerve cells can produce and release exosomes.
Exosomes contain a variety of biologically active substances related to cell sources, including proteins, lipids, and a variety of RNA molecules, which can directly reflect the physiological and pathological state of secreting cells, and can directly activate receptor cells through cell membrane receptors. Release biologically active substances to recipient cells and participate in cell-to-cell communication.
Exosomes play an important role in the activities of the nervous system, participating in processes such as synaptic plasticity, neuronal stress response, intercellular communication and neurogenesis, and mediating the interaction between the central nervous system (CNS) and the systemic system. Recent studies have shown that exosomes can pass through the blood-brain barrier and are highly stable, have low immunogenicity and other characteristics, and are easy to be detected in peripheral tissues.
Exosomes in CNS can be sent across the blood-brain barrier to reach the blood. By separating neurogenic exosomes in the blood, exosomes-related biomarkers can be identified, and targeted clinical diagnosis methods can be developed; At the same time, exosomes can also be used as drug carriers to carry out targeted delivery of disease treatment drugs, solve the problem of drug transmission caused by the blood-brain barrier, and contribute to the development of CNS disease drugs.
Nyuen Biotechnology has built a complete exosomes technology platform, which can realize the separation of plasma total exosomes and the separation of plasma neurogenic exosomes.
Among them, the total plasma exosomes obtained by the self-developed plasma total exosomes separation technology, compared with existing plasma total exosomes separation kits, such as SBI's ExoQuick kit, has high purity and less impurity protein. Easy operation and other advantages.
The self-developed domestic first plasma neurogenic exosomes separation technology is based on the principle of immune capture. The content of the separated plasma neurogenic exosomes is analyzed, for example, through qPCR and ELISA techniques, which can be used for Companion diagnosis of disease.
